Safety Alerts & Recalls
What does this mean?
Following the FDA's detailed review of Spiriva safety data, patients treated with Spiriva do not need to worry about an added risk of stroke or heart attack. If you have any questions about the FDA's review of this safety issue, or if you have concerns about side effects from Spiriva, please follow up with your doctor or other healthcare provider.
Follow-Up to the FDA Safety Review of Tiotropium (marketed as Spiriva Handihaler)
The U.S. Food and Drug Administration (FDA) announced that data from a recent review of Spiriva show no increased risk of stroke, heart attack, or death in patients using the medicine.
Spiriva contains the active ingredient tiotropium, a long-acting respiratory treatment for chronic obstructive pulmonary disease (COPD). COPD is a serious and chronic lung disease that restricts air flow in the lungs resulting in shortness of breath. In the United States, COPD includes two main conditions - emphysema and chronic bronchitis.
For more information, please visit: more information here